November 26, 2020
ASKA Pharmaceutical said on November 25 that its gonadotropin-releasing hormone (GnRH) receptor antagonist Relumina Tablets (relugolix), also known as TAK-385, hit the primary endpoint in a Japan PIII study for the treatment of endometriosis. Relumina was approved in Japan in...read more